Evidence map›Paper›PMID 42102091›Full record

ArticlePloS one2026

Estimating HIV incidence and assessing associated risk factors among adults: Evidence from the 2018-2022 HIV vaccine preparedness cohort in Masaka, Uganda.

Sylvia Kusemererwa, Sheila Kansiime, Gertrude Mutonyi, Ayoub Kakande, Shamim Nabukenya, Aeron Namirembe, Naphtal Erima, Doreen Joan Asio, Elizabeth Mbabazi Atuhura, Shamim Ssendagire and 6 more

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sylvia KusemererwaMedical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.ORCID https://orcid.org/0000-0002-1390-109X
Sheila KansiimeMedical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.
Gertrude MutonyiMedical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.
Ayoub KakandeMedical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.
Shamim NabukenyaMedical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.
Aeron NamirembeMedical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.
Naphtal ErimaMedical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.
Doreen Joan AsioMedical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.
Elizabeth Mbabazi AtuhuraMedical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.
Shamim SsendagireMedical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.
Martin OnyangoMedical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.
Julie FoxKing's College London, London, United Kingdom.
Sheena McCormackMedical Research Council Clinical Trials Unit, London, United Kingdom.
Pontiano KaleebuMedical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.
Eugene RuzagiraMedical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.
PrEPVacc Study Team

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDespite global reports of declining HIV incidence, current data are limited. This study presents findings on HIV incidence and risk factors in a HIV trial preparedness cohort.

methodsBetween 18 July 2018 and 13 October 2022, individuals 18-45-year-old were recruited from communities along the trans-African highway and the shores of Lake Victoria in Masaka district, Uganda. Eligible individuals were HIV-negative and met at least one of the following criteria: suspected or confirmed sexually transmitted infection (STI), unprotected sex with ≥2 partners, unprotected sex with a new partner in the past 3 months, or unprotected sex in exchange for money/goods in the past month. Baseline data included demographics, sexual behaviour, and HIV risk factors. Follow-up assessments of HIV risk and sexual behaviour were conducted every six months, while HIV counselling and testing (HCT) were provided every 3 months, with linkage to care for those testing positive. Data were summarised descriptively, and associations with HIV incidence were analysed using uni-variable and multi-variable Poisson regression models.

resultsOf the 1422 individuals enrolled, 1115 (78.4%) attended ≥1 follow-up visit; 69% were female and 55% were aged ≤24 years. Over 900.3 person-years of observation (PYO), 24 individuals acquired HIV, yielding an incidence rate (IR) of 2.7 PYO [95% Confidence Interval (CI): 1.8-4.0]. Baseline factors independently associated with incident HIV included female sex [adjusted incidence rate ratio (aIRR) = 6.84 PYO, 95% CI 1.60-29.30], residence in a fishing community [aIRR = 3.04 PYO, 95% CI 1.05-8.78] and recreational drug use in the past 3 months [aIRR = 3.08 PYO, 95% CI 1.19-7.99]. In a separate analysis, using time-updated variables assessed during follow-up, HIV acquisition was associated with sex after alcohol consumption [aIRR = 2.65 PYO, 95% CI 1.11-6.31], and STI diagnosis/treatment within the past 3 months [aIRR = 2.52 PYO, 95% CI 1.09-5.80].

conclusionHIV incidence remains high among women, fishing community residents, and individuals with high risk behaviours, underscoring the need for targeted interventions to reduce the burden in these populations.

Indexed as

AIDS VaccinesHIV InfectionsAdolescentAdultCohort StudiesFemaleHumansIncidenceMaleMiddle AgedRisk FactorsSexual BehaviorUgandaYoung AdultAIDS Vaccines

Identifiers

PMID42102091
PMCPMC13155609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.